“Clinical trial recruitment success starts not by searching for the perfect patients for a study, but by recruiting interested patients and matching them with the perfect trial.” – Michael J. Koren, MD, FACC, FAPCR, CPI
Problem:
A large pharmaceutical company conducting an extensive, multi-center statin study struggled with site recruitment and enrollment.
Problem Solved:
ENCORE Research Group leveraged relationships with insurance companies and sites across Florida to enroll 500 of the 2,400 subjects and to oversee operations in nearly half the enrolling sites nationwide.
Koren MJ, Hunninghake DB. J Am Coll Cardiol. 2004 Nov;44(9):1772-1779.
Problem:
A large laboratory company posited that a specific panel of biomarkers could identify peripheral vascular disease but didn’t have data in a primary care population.
Problem Solved:
ENCORE Research Group designed, executed and completed, throughout the network of its sites, a 200 patient study in less than ten months, demonstrating the biomarkers to be ineffective in general populations and providing significant savings to the company.
Problem:
A pharma company with an innovative heart failure product faced recruitment and enrollment challenges in a Phase 1 study for African Americans with a specific phenotypic variation.
Problem Solved:
ENCORE Research Group employed creative recruitment strategies to quickly identify a large number of potential subjects and randomize over half of all patients recruited globally. Local doctors were engaged to reach out to their patients with great success, screening over 30 difficult-to-find patients.
Problem:
An Israeli medical technology start-up company innovated and developed a device to administer heat, vibration, and motion simultaneously. The study was placed at a large medical academic center with poor recruitment results.
Problem Solved:
ENCORE Research Group rescued the enrollment in the study. Working with a local orthopedic group, ENCORE led a research team to complete the enrollment of 70 patients in six months and published results. Based on the published report, the device company secured lucrative money from a large international group.
Kitay GS, Koren MJ, Helfet DL, et al. Osteoarthritis and Cartilage. 2009 Oct;17(10):1269-74.
Problem:
A small, local company developed a promising topical treatment for acne. The development team reached out to ENCORE Research Group for assistance with protocol development and trial execution.
Problem Solved:
ENCORE Research Group investigators wrote the protocol and provided regulatory, recruitment, operational oversight, and database design. Sixty patients were enrolled and completed in four months. All this enabled the ENCORE investigators to collect data and publish the results.
Bernhardt MJ, Myntti MF. J Drugs in Dermatol. 2016 June;15(6):677-683.
Problem:
A local research and development company launched a research trial with a large medical research center to study treatment of chronic foot ulcers. Enrollment lagged for nine months.
Problem Solved:
ENCORE’s River City Clinical Research site came on as a rescue site, finishing enrollment of 30 patients in six months as the top enroller in both control and treatment groups.
ENCORE Research Group goes above and beyond for patients. When an ENCORE patient completed a pivotal trial with mixed results and learned the sponsor was facing challenges with the FDA, she volunteered to go to Washington and testify on behalf of the medication she believes saved her life. She is a true proponent of Dr. Michael Koren’s statement, “It’s not just about turning a profit, it’s about caring for our patients”.